Filing Details

Accession Number:
0001415889-23-015711
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-01 19:31:40
Reporting Period:
2023-11-29
Accepted Time:
2023-12-01 19:31:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
855654 Immunogen Inc. IMGN Pharmaceutical Preparations (2834) 042726691
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1510720 Theresa Wingrove C/O Immunogen, Inc.
830 Winter Street
Waltham MA 02451
Svp Of Regulatory Affairs No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-11-29 6,792 $10.65 9,603 No 4 M Direct
Common Stock Disposition 2023-11-29 6,792 $16.66 2,811 No 4 S Direct
Common Stock Acquisiton 2023-11-30 133,691 $10.65 136,502 No 4 M Direct
Common Stock Acquisiton 2023-11-30 30,733 $10.79 167,235 No 4 M Direct
Common Stock Disposition 2023-11-30 164,424 $28.95 2,811 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2023-11-29 6,792 $0.00 6,792 $10.65
Common Stock Stock Option (Right to Buy) Disposition 2023-11-30 133,691 $0.00 133,691 $10.65
Common Stock Stock Option (Right to Buy) Disposition 2023-11-30 30,733 $0.00 30,733 $10.79
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
133,691 2028-02-15 No 4 M Direct
0 2028-02-15 No 4 M Direct
9,267 2024-07-17 No 4 M Direct
Footnotes
  1. Effected pursuant to a trading plan adopted on June 13, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.69, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
  3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $29.28, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
  4. This option was granted on 2/15/2018 and is fully vested as of the transaction date.
  5. This option was granted on 7/17/2014 and is fully vested as of the transaction date.